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Methodology
Results Summary & Conclusions
Funding
• 34 subjects (17 female)
• UO Evonuk Environmental chamber simulated conditions at 
~15,600 ft (11.5% oxygen)
• AMS scores and plasma samples collected before entering the 
chamber, at 4 hours, 7 hours, 10 hours, and after breathing 
oxygen from outside the chamber
• AMS scores assessed using the Lake Louise Questionnaire 
(LLQ) and Environmental Symptoms Questionnaire (ESQ)
• Plasma samples were stored at -80°C in a freezer
• Plasma samples were assayed for 13 inflammatory markers 
using a 13-Plex Bead Based Assay Kit (LegendPlex, BioLegend)
• Inflammatory markers include: IL-1β, INF-ɑ2, IFN-γ, TNF-ɑ, 
MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33, 
and IL-10
• Beads were divided by size and internal fluorescence intensity to 
determine the quantity of each cytokine in the sample
Results
References
• IL-8 significantly increased in AMS- but not 
AMS+ participants regardless of the AMS 
definition. This indicates that IL-8 may be 
important in reducing  AMS susceptibility by the 
activation of neutrophils that IL-8 causes 
(Figure 1)
• The change in [IL-1b] was not significant for 
AMS+ subjects for definition 1, 3, & 5. IL-1b
helps lymphocytes fight infections, so AMS-
subjects may have additional protection during 
hypoxia (Figure 2)
• AMS- subjects, not AMS+ subjects, 
significantly increased [IL-33] for definitions 3, 
4, and 5 so IL-33 is not involved in altitude 
headaches (Figure 3)
• The AMS definition used may alter the 
observed relationships between AMS and 
systemic inflammation.
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Table 1. Comparing the number of AMS- and AMS+ participants 
for each AMS definition.
Figure 1. Change in [IL-8] from baseline to 10 hours in AMS- and 
AMS+ subjects comparing AMS definitions. Note that AMS- subjects 
significantly increase [IL-8] while AMS+ subjects do not. *p<0.05 paired 
t-test. Mean ± SEM.
Figure 2. Change in [IL-1β] from baseline to 10 hours in AMS- and 
AMS+ subjects comparing AMS definitions. Note that there is a 
significant increase in [IL-1β] for all subjects except AMS+ subjects for 
definitions 1, 3, and 5. *p<0.05 paired t-test. Mean ± SEM.
Figure 3 Change in [IL-33] from baseline to 10 hours in AMS- and 
AMS+ subjects comparing AMS definitions. Note that AMS- subjects 
significantly increase [IL-33] only for definitions 3, 4, and 5. *p<0.05 
paired t-test. Mean ± SEM.
Introduction
The low oxygen levels that exist at high altitudes are often a 
difficulty for those that live, work, and travel to these extreme 
environments. Most people successfully adjust to the low partial 
pressure of oxygen, while those who do not use proper 
acclimatization or ascent profiles can develop acute mountain 
sickness (AMS). AMS occurs when individuals go too high in 
altitude too quickly. The pathophysiology behind AMS remains 
unknown, however, AMS is associated with hypoxemia (low blood 
oxygen) which everyone gets when going to high altitude 
(Loeppky et. al., 2008). Hypoxia at altitude increases 
inflammation and AMS is reported to be associated with systemic 
inflammation as measured by elevated cytokines such as 
interleukins (Wang, 2018). AMS was defined by the following 
definitions: 1) Lake Louise Questionnaire (LLQ) score ³3 and a 
headache score ³1 at the 10-hour time point, 2) maximum LLQ 
score ³3 and a maximum headache score of ³1, 3) maximum 
LLQ score ³3 and a maximum Environmental Symptoms 
Questionnaire (ESQ) score of 0.7 or maximum LLQ ³3, a 
maximum headache score ³2, and a maximum ESQ ³0.4, 4) 
maximum LLQ ³3, 5) LLQ score ³3 at the 10-hour time point. The 
purpose of this study was to determine if the AMS definition used 
















































































Subject ID Definition 1 Definition 3 Definition 5 Definition 2 Definition 4
AMS-075 AMS- AMS- AMS- AMS- AMS-
AMS-012 AMS- AMS- AMS- AMS- AMS-
AMS-082 AMS- AMS- AMS- AMS- AMS-
AMS-049 AMS- AMS- AMS- AMS- AMS-
AMS-070 AMS- AMS- AMS- AMS- AMS-
AMS-150 AMS- AMS- AMS- AMS- AMS-
AMS-627 AMS- AMS- AMS- AMS- AMS-
AMS-001 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-808 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-021 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-092 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-376 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-120 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-404 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-017 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-061 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-273 AMS+ AMS+ AMS+ AMS+ AMS+
AMS-039 AMS- AMS- AMS- AMS+ AMS+
AMS-298 AMS- AMS- AMS- AMS+ AMS+
AMS-044 AMS- AMS- AMS+ AMS- AMS+
AMS-101 AMS- AMS- AMS+ AMS+ AMS+
AMS-232 AMS- AMS+ AMS+ AMS- AMS+
AMS-313 AMS- AMS+ AMS- AMS+ AMS+
AMS-072 AMS- AMS- AMS+ AMS+ AMS+
AMS-653 AMS- AMS+ AMS+ AMS- AMS+
AMS-048 AMS+ AMS- AMS- AMS+ AMS+
AMS-018 AMS+ AMS- AMS- AMS+ AMS+
AMS-014 AMS+ AMS- AMS- AMS+ AMS+
AMS-052 AMS+ AMS- AMS- AMS+ AMS+
AMS-927 AMS- AMS+ AMS+ AMS+ AMS+
AMS-034 AMS- AMS+ AMS+ AMS+ AMS+
AMS-523 AMS- AMS+ AMS+ AMS+ AMS+
AMS-045 AMS+ AMS- AMS+ AMS+ AMS+
AMS-921 AMS+ AMS+ AMS- AMS+ AMS+
AMS- Subjects 18 17 15 10 7
AMS+ Subjects 16 17 19 24 27
